# Thymox Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/thymox-technology

- Industry: Chemicals
- Headquarters: Sherbrooke, Canada
- Website: www.thymox.com
- Total disclosed funding: $4.6M
- Latest round: Series B (May 8, 2017)
- Investors on record: 2

## About

Thymox Technology specializes in creating biodegradable antimicrobial products that effectively combat harmful pathogens, leveraging the natural properties of thymol derived from thyme oil to deliver environmentally friendly disinfection solutions.Thymox Technology develops innovative antimicrobial solutions aimed at various sectors. Founded by Serge Auray, the company is headquartered in Sherbrooke, Canada. In May 2017, Thymox secured USD 4.6 mn in a Series B funding round led by Cycle Capital Management and Desjardins Capital, raising a total of USD 4.6 mn to date.Thymox, a brand under Laboratoire M2, specializes in biodegradable, high-performance antimicrobial products with thymol as the active ingredient. Its offerings include disinfectants for surfaces, farms, greenhouses, biopesticides, and animal hoof care products, effectively targeting pathogens including bacteria and viruses. Thymox distributes its products across North America and Europe, addressing the needs of agricultural, animal health, and commercial cleaning sectors with a focus on eco-friendly solutions.Thymox primarily operates through B2B transactions, catering to distributors and commercial entities. Its revenue model is driven by the sale of products like the Thymox Disinfectant Spray, provided under various arrangements. While specific pricing details are undisclosed, the products are positioned competitively within the market, reflecting strong demand in the disinfectant sector.Thymox plans to leverage its recent funding from the USD 4.6 mn Series B round to enhance its product offerings and expand into new markets. The company is focusing on developing new antimicrobial products targeted for launch in the coming years and aims to penetrate additional regions beyond North America and Europe. This strategic initiative is expected to enhance Thymox's market position and drive further growth.

## Funding rounds

- Series B, May 8, 2017, $4.6M — Cycle Capital Management, Desjardins Capital

## Investors

- Cycle Capital Management (https://capitalatlas.ai/funds/cycle-capital-management) — Series B
- Desjardins Capital (https://capitalatlas.ai/funds/desjardins-capital) — Series B